Results 241 to 250 of about 74,894 (279)
Some of the next articles are maybe not open access.
Journal of the American Academy of Dermatology, 1991
Hydroxyurea's place in the scheme of psoriasis therapy has diminished in recent years. Some practitioners mistakenly believe that it is used only in desperate situations, is of little or no benefit in patients unresponsive to more conventional systemic therapies, and may predispose patients to the development of secondary malignancies.
A S, Boyd, K H, Neldner
openaire +2 more sources
Hydroxyurea's place in the scheme of psoriasis therapy has diminished in recent years. Some practitioners mistakenly believe that it is used only in desperate situations, is of little or no benefit in patients unresponsive to more conventional systemic therapies, and may predispose patients to the development of secondary malignancies.
A S, Boyd, K H, Neldner
openaire +2 more sources
Mutation Research/Reviews in Genetic Toxicology, 1975
Hydroxyurea (HU) is an anti-leukaemia and anti-tumour drug which has also found limited application in the treatment of dermatological disorders. It is a potent inhibitor of DNA synthesis in many organisms from viruses to man and in cell culture systems. To a lesser degree it can also inhibit RNA and protein synthesis.
openaire +2 more sources
Hydroxyurea (HU) is an anti-leukaemia and anti-tumour drug which has also found limited application in the treatment of dermatological disorders. It is a potent inhibitor of DNA synthesis in many organisms from viruses to man and in cell culture systems. To a lesser degree it can also inhibit RNA and protein synthesis.
openaire +2 more sources
Hydroxyurea derivatives—1-methyl-1-hydroxyurea and 1-ethyl-1-hydroxyurea
Biochemical Pharmacology, 1968Abstract Certain aspects of the biochemical pharmacology of 1-methyl-1-hydroxyurea (MHU) and 1-ethyl-1-hydroxyurea (EHU) were investigated and were contrasted with the actions of hydroxyurea (HU). Assay of inhibitory action against DNA synthesis in an ascites tumor cell system in vitro revealed an order of relative potentcy of MHU > HU > EHU ...
openaire +2 more sources
British Journal of Dermatology, 2006
SUMMARY Nine patients who were treated for psoriasis with hydroxyurea displayed peripheral macrocytosis. Mild megaloblastic changes were also seen in the bone marrow of three patients. One patient receiving hydroxyurea developed mild anaemia, another leukopenia. Macrocytosis did not appear to be secondary to an alteration in serum B12 or folate levels.
S, Spier +3 more
openaire +3 more sources
SUMMARY Nine patients who were treated for psoriasis with hydroxyurea displayed peripheral macrocytosis. Mild megaloblastic changes were also seen in the bone marrow of three patients. One patient receiving hydroxyurea developed mild anaemia, another leukopenia. Macrocytosis did not appear to be secondary to an alteration in serum B12 or folate levels.
S, Spier +3 more
openaire +3 more sources
Medical Journal of Australia, 1980
A case of hydroxyurea-induced self-limited hepatitis with an influenza-like reaction to hydroxyurea therapy is presented. The association was supported by recurrence of the symptoms on rechallenge with the drug.
R, Heddle, A F, Calvert
openaire +2 more sources
A case of hydroxyurea-induced self-limited hepatitis with an influenza-like reaction to hydroxyurea therapy is presented. The association was supported by recurrence of the symptoms on rechallenge with the drug.
R, Heddle, A F, Calvert
openaire +2 more sources
Hydroxyurea Administered Intermittently
JAMA: The Journal of the American Medical Association, 1965THE SYNTHESIS of hydroxyurea (Hydrea) was reported in 1869 by Dresler and Stein. 1 In animal studies, Rosenthal et al 2 found that the compound produced anemia, severe leukopenia, and megaloblastic changes in the peripheral blood and bone marrow. Recently, this compound has been introduced into cancer chemotherapy. Tumor responses have been observed in
H J, LERNER, G L, BECKLOFF
openaire +2 more sources
Healthcare utilization and hydroxyurea adherence in youth with sickle cell disease
Pediatric Hematology & Oncology, 2018Background: Sickle cell disease (SCD) complications lead to poor health-related quality of life (HRQOL) and increased healthcare utilization in this population, which could be mitigated with hydroxyurea therapy; however, adherence is suboptimal.
S. Badawy +4 more
semanticscholar +1 more source
Hydroxyurea-induced leg ulcers
Hospital Medicine, 2000Hydroxyurea is an analogue of urea that inhibits DNA synthesis. It inhibits ribonucleotide reductase, the enzyme which converts ribonucleotide diphosphates to their deoxyribonucleotide forms. This causes selective killing of cells in the S phase of the cell cycle.
J, Murphy, S M, Morley
openaire +2 more sources
Hydroxyurea: Mechanism of Action
Science, 1963Acetohydroxamic acid has been identified, by paper chromatography, in the blood of three patients with chronic myelogenous leukemia on hydroxyurea therapy. This suggests that the drug is hydrolyzed yielding hyroxylamine, which then cleaves thioesters, in particular acetyl-coenzyme A.
W N, FISHBEIN, P P, CARBONE
openaire +2 more sources